Science-Based Innovation-Focused ADC Company. Corporate Overview August 2018
|
|
- Gillian Lamb
- 5 years ago
- Views:
Transcription
1 Science-Based Innovation-Focused ADC Company Corporate Overview August 2018
2 Forward-Looking Statements This presentation, in addition to historical information, contains certain forwardlooking statements made pursuant to the Private Securities Litigation Reform Act of Such statements may involve significant risks and uncertainties, and actual results could differ materially from those expressed or implied herein. Factors that could cause such differences include, but are not limited to, new product development (including clinical trials outcome and regulatory requirements/actions); competitive risks to marketed products; forecasts of future operating results; availability of required financing and other sources of funds on acceptable terms, if at all; as well as those discussed in the Company's filings with the Securities and Exchange Commission. 2
3 Our Company Vision for Value Creation Immunomedics is deeply committed to become the leading antibody-drug conjugate (ADC) company worldwide delivering breakthrough therapies to treat complex cancers and transform patient outcomes 3
4 First-in-class ADC Platform Suite of Humanized Antibodies for Creating ADCs 1. hrs7, used in sacituzumab govitecan, targets Trop-2 for solid cancers 2. Labetuzumab, used in IMMU-130, targets CEACAM5 for colorectal cancer 3. IMMU-114, used in IMMU-140, targets HLA-DR for solid and liquid cancers Linker for SN-38 SN-38 Payload 1. SN-38 more potent than parent compound, irinotecan 2. In xenograft models, ADC delivers up to 136-fold more SN-38 than irinotecan Linker for SN Hydrolysable linker for payload release 2. High drug-to-antibody ratio (7.5:1) 4
5 Sacituzumab Govitecan, an Antibody-Drug Conjugate for Targeted Drug Delivery to Solid Cancers Target: Trop-2 Pan-epithelial cancer antigen with broad expression in many different cancers 80% of patients have moderate to strong expression by immunohistochemistry Internalizes upon antibody binding - ideal target for drug delivery with antibody-drug conjugates Trop-2 expression in TNBC liver tumor biopsy Antibody: Humanized RS7-3G11 Binds human breast, lung, colon, renal, prostate, urothelial, and many other solid cancers 5
6 Significant Progress with Sacituzumab Govitecan vs. Key Milestones BLA submission for 3 rd line metastatic triple-negative breast cancer (mtnbc) accepted and granted Priority Review by FDA PDUFA date set for January 18, 2019 Initiation of pivotal Phase 2 TROPHY U-01 study in metastatic urothelial cancer (muc) Multiple clinical/preclinical collaborations to advance into earlier lines of treatment and other cancer indications AstraZeneca/MedImmune: sacituzumab govitecan + durvalumab combo in 1 st line mtnbc and muc Clovis: sacituzumab govitecan + rucaparib combo in 2 nd line mtnbc and muc Yale: monotherapy in endometrial and cervical cancers Wisconsin: monotherapy in prostate cancer Preclinical studies in head and neck and prostate cancers Launch preparation ongoing, commercial manufacturing on track to meet demand 6
7 Building a Blockbuster Brand in Oncology Cancer Types Line of Therapy 3 rd Line+ 2 nd Line 1 st Line (Neo)Adjuvant mtnbc Mono Mono/ PARPi combo Mono CPI combo CPI combo muc Cisplatin-eligible Cisplatin-ineligible Mono +PARPi Mono CPI combo Mono +PARPi CPI combo ER+ mbc Mono NSCLC Mono/CPI combo Ongoing Planned Evaluating 7
8 Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer
9 Low Response Rates in Pre-treated mtnbc* Drug Phase N Population ORR (%) PFS (mos) OS (mos) 1st line treatment Carboplatin st line Docetaxel st line Cisplatin/ Carboplatin st line (80.2%) Ixabepilone 3 2 (pooled analysis) 60 >1st line treatment Resistant to anthracycline, cyclophosphamide & taxane or taxane only Capecitabine 3 3 (pooled analysis) 208 Prior or resistant to anthracycline & taxane Eribulin 4 3 (pooled analysis) 199 > 1 prior chemo * Includes breast cancer drugs with data from Phase 2/3 s with minimum mtnbc sample size > 60; ORR and PFS data Source of data: 1) Tutt A, SABCS 2014; 2) Isakoff SJ, J Clin Oncol 2015; 3) Perez EA, Breast Can Res Treat 2010; 4) Pivot X, Ann Oncol
10 Adverse Events (Regardless of Causality) Body system Adverse event All grades Grade 3 or 4 Neutropenia 63% 41% Hematologic Febrile neutropenia 8% 7% Anemia 52% 10% Leukopenia 24% 14% Nausea 63% 5% Gastrointestinal Diarrhea 56% 8% Vomiting 46% 5% Constipation 32% 1% Fatigue 50% 7% Alopecia 36% NA Other Decreased appetite 30% 0% Hyperglycemia 23% 4% Hypomagnesemia 21% 1% Hypophosphatemia 15% 8% Includes all events >20% (all grades) or >5% (grade 3 or 4); NA = not applicable Adverse events were managed with supportive medication or dose modifications 25% of patients had dose modifications predominantly to 7.5 mg/kg Two patients (1.8%) discontinued due to adverse events (grade 3 transient infusion reaction/grade 2 fatigue) There were no treatment-related deaths 10
11 Sacituzumab Govitecan in Late-Line mtnbc 108 patients in BLA Patients received 3rd prior line for metastatic disease: 100% ORR: 33% (local), 32% (BICR) Median DoR: 8.3 months (local), 6.7 months (BICR) Median PFS: 5.5 months (local) Percent Reduction in Baseline Target Lesions* * Two patients did not meet the criteria of two prior therapies for metastatic disease and were not included in the BLA package 11
12 Amended ASCENT Phase 3 Study (under SPA): Overview mtnbc (ASCO/CAP) R/R after 2 prior SOC chemo for advanced disease OR 1 therapy for advanced disease who also progressed within 12 months of (neo)adjuvant therapy N = 488 Stratification Factors # prior therapies Geography +/- known BM (15% cap) Sacituzumab govitecan 10 mg/kg IV d1 & 8, every 3 wks Treatment of physician choice Capecitabine Eribulin Gemcitabine Vinorelbine Continue treatment until progression 1 o Endpoint PFS ( BM-) 2 o Endpoints OS (BM-) PFS (ITT) OS (ITT) First patient dosed in November 2017 in U.S. SPA protocol accepted by EU regulatory authority Clinical trial accruing globally National Institutes of Health. Accessed March 14,
13 Triple-Negative Breast Cancer Stage 1, 2 and 3 (resectable) Neoadjuvant Potential for CPI or other combo Adjuvant Stage 3 locally advanced (unresectable), Stage 4 metastatic Phase 1/2 CPI combo 1 st Line (10-11k Pts) Phase 2 single arm 2 nd Line (9-10k Pts) 3rd Line+ (8-9k Pts) Phase 2 single arm Phase 1/2 PARPi combo BLA submitted Phase 3 confirmatory ASCENT Evaluating Planned Ongoing 13
14 Sacituzumab Govitecan in Advanced Urothelial Cancer
15 Low Response Rates in Relapsed / Refractory muc Treatment Phase ORR PFS (months) OS (months) Source Historical ~10% Vinflunine 3 8.6% Docetaxel 2 8.9% Bellmunt J Clin Oncol 2009 Petrylak D J Clin Oncol 2016 Docetaxel + Ramucirumab 2 24% Petrylak D J Clin Oncol 2016 Docetaxel 3 14% 2.8 Not Reported Petrylak D Lancet 2017 Docetaxel + Ramucirumab % 4.1 Not Reported Petrylak D Lancet
16 B e s t R e s p o n s e B e s t % c h a n g e in T L fr o m b a s e lin e S D P D Sacituzumab Govitecan in 2 nd Line muc 41 patients enrolled Median number of prior lines: 3 (range, 1 6) ORR: 34% (14/41) Prior CPI: 29% (4/14) Median duration of response: 12.6 months (95% CI: 7.5, 12.9) Clinical benefit rate (CR+PR+SD 6 months): 49% Percent Reduction in Baseline Target Lesions C o m p le te r e s p o n s e P a r tia l r e s p o n s e S ta b le d is e a s e P r o g r e s s io n P rio r c h e c k p o in t in h ib ito r T x 72% (26/36) of patients with at least one CT response assessment had reduction of target lesions (sum of diameters) Tagawa et al, Annals of Oncology (2017) 28 (suppl_5): v295-v /annonc/mdx371 16
17 muc Phase 2 Pivotal TROPHY U-01 Study Overview muc Cohort 1: 3rd line post platinumand PD-1/PD-L1 based therapies OR Cohort 2: 2nd line for cisplatinineligible patients Cohort 1: N = 100 Cohort 2: N = 40 Sacituzumab govitecan 10 mg/kg IV d1 & 8, every 3 wks Continue treatment until progression 1 o Endpoint 2 o Endpoints ORR (BICR) DoR PFS OS Patients will be enrolled across approximately 50 sites in North America and Europe 17
18 Metastatic Urothelial Cancer Cisplatin eligible Cisplatin ineligible 1 st Line (8-10k Pts) 1 st Line (10-12k Pts) Phase 1/2 CPI combo Phase 1/2 CPI combo 2 nd Line (6-7k Pts) Phase 1/2 PARPi combo 2 nd Line (7-8k Pts) TROPHY U-01 Study Phase 1/2 PARPi combo 3rd Line+ (3-4k Pts) TROPHY U-01 Study 3rd Line+ (3-4k Pts) TROPHY U-01 Study Evaluating Planned Ongoing 18
19 Sacituzumab Govitecan in ER+/HER2 Metastatic Breast Cancer
20 Estrogen-Receptor Positive/HER2-Negative mbc Most common form of mbc in the U.S. Treatments involve: Initially endocrine-based therapies, including CDK 4/6 inhibitors Subsequently chemotherapy, but response rates to later-line therapies are low Poor prognosis for patients with visceral metastases U.S. Stage 4 Breast Cancer Prevalent Population Distribution by Subtype (SEER) 9% 17% 13% 61% ER+/HER2neg ER+/HER2+ ERneg/HER2+ TNBC New therapeutic options needed for treatment-refractory ER+/HER2 mbc 20
21 Low Response Rates to Chemotherapy in Pre-Treated mbc Drug N* Population HR+ % ORR % PFS (months) OS (months) Source Ixabepilone 126 Prior A, T and capecitabine Perez EA JCO 2007 Capecitabine 548 Capecitabine ER+ subgroup Eribulin ER+ subgroup Prior A, T 3 prior chemo (incl. adjuvant) Idem 100 NA Idem 100 NA Kaufman PA JCO 2015 Twelves C, Breast Cancer Research, 2016 Twelves C, Breast Cancer Research, 2016 Eribulin 508 Prior A and T 2 prior chemo Cortes J Lancet 2010 Vinorelbine 115 Prior A, 2 lines ** 7.5 Jones JCO 1995 A: Anthracycline; T: Taxane. *N represents mbc population which includes HER2+ and/or TNBC; ORRs are based on local review. ** TTF 21
22 Single-Arm, Open-Label Study Design ER+/HER2 mbc at last biopsy Sacituzumab govitecan 10 mg/kg IV d1 & 8, every 3 wks Continue treatment until progression/ unacceptable toxicity Key Eligibility Criteria Adults, 18 years of age ECOG: prior metastatic therapies Measurable disease Evaluations Response by local assessment (RECIST v1.1) Other: safety 22
23 Demographics and Patient Characteristics (N=54) Female/male, n 54/0 Median age, years (range) 54 (33-79) ECOG performance status 0 1 Missing 35% 56% 9% Taxane any setting Anthracycline any setting CDK 4/6 inhibitors mtor inhibitors 93% 69% 69% 54% Median time from metastatic disease to study entry, years 1 prior chemotherapy line for metastatic disease % Prior chemotherapy for metastatic disease Fluoropyrimidine agents Taxane Eribulin Platinum agents 80% 57% 33% 24% Median number of metastatic chemotherapy lines Median number of metastatic hormonal therapy lines Median number of prior metastatic treatment lines Hormonal therapy for metastatic disease 3 lines of hormonal therapy for metastatic disease 2 (0-9)* 3 (1-6)* 5 (2-17)* 100%* 67%* Sites of metastatic disease at study entry ** Bone Liver Chest Lung 80% 82% 37% 31% *Includes lines of therapy given in the (neo)adjuvant setting if patient became metastatic within 12 months (N=4) ** Metastatic sites in >20% patients; 89% (48/54) of patients had liver or lung metastases 23
24 Adverse Events (Regardless of Causality) All events >20% or Grade 3+ >5% Body system Adverse event (AE) All grades* Grade 3 or 4* Hematologic Gastrointestinal Other Neutropenia Febrile neutropenia Anemia Leukopenia Nausea Diarrhea Vomiting Constipation Fatigue Alopecia Decreased appetite Cough Alk Phos increase Hypophosphatemia 64% 2% 36% 16% 58% 40% 38% 30% 46% 36% 28% 22% 20% 16% 42% 2% 6% 8% 2% 4% 4% 0% 2% NA 0% 0% 6% 8% ** AE frequency based on the available reporting of 50/54 pts. AE data for the remaining 4/54 patients are being collected AEs managed with supportive medication or dose modifications 28% received growth factor support 22% of patients had dose reduced to 7.5 mg/kg; 9% occurring in 1 st cycle Two patients (3.7%) discontinued due to AEs (grade 3 neutropenia not recovered within 3 weeks; grade 3 diarrhea/ dehydration) No treatment-related deaths 24
25 B e s t R e s p o n s e (% c h a n g e in ta rg e t le s io n fro m b a s e lin e ) Tumor Response to Sacituzumab Govitecan Local Response Evaluation by RECIST1.1 Objective response rate CR PR 31% (17/54) Clinical benefit rate (CR+PR+SD 6 months) 48% (26/54) P a r tia l r e s p o n s e S ta b le d is e a s e P r o g r e s s io n 6 p ts w ith o u t C T a s s e s s m e n t a r e n o t s h o w n + C o n tin u in g tre a tm e n t % (34/54) of patients with at least one CT response assessment had reduction of target lesions (sum of diameters) Median number of metastatic chemo lines: 2 Median number of prior metastatic lines: 5 25
26 Response Onset and Durability (N=17) // (2 6.1 ) Median duration of response: 7.4 months (95% CI: 4.4, 18.3) N o p r io r C D K 4 /6 in h ib ito r P r io r C D K 4 /6 in h ib ito r C o n tin u in g O n s e t o f r e s p o n s e Median time to onset of response: 2.3 months (range: ) 7 responders were still receiving sacituzumab govitecan at last assessment M o n th s fro m s ta rt o f s a c itu z u m a b g o v ite c a n Best response under RECIST 1.1, as per local assessment 26
27 Progression-Free Survival (PFS) Months Number at risk Based on Local Assessment using RECIST 1.1 Median PFS, months (95% CI) 6.8 (4.6, 8.9) 32 patients had objective progression (maturity = 59%) 10 patients are continuing 12 other patients censored 5 with no CT assessment were censored at baseline 1 withdrew at 0.7 months after leaving study with AE The remaining censored pts left study with their last response assessment SD or better 27
28 Response to Sacituzumab Govitecan in Subgroups ORR, % (n/n) Overall 31% (17/54) Age <65 65 Visceral involvement at study entry (Liver/Lung) Yes No Liver involvement 29% (12/42) 42% (5/12) 27% (13/48) 67% (4/6) 27% (12/44) Onset of metastatic disease from diagnosis < 1 year 1 year 2 prior chemo for metastatic disease* < 2 prior chemo for metastatic disease* 3 prior hormonal therapies for metastatic disease* < 3 prior hormonal therapies for metastatic disease* ORR, % (n/n) 15% (2/13) 37% (15/41) 29% (12/41) 38% (5/13) 25% (9/36) 44% (8/18) Clinical Benefit Rate in patients with liver involvement (CR+PR+SD 6 months) 48% (21/44) Prior CDK 4/6 inhibitors No prior CDK 4/6 inhibitors 24% (9/37) 47% (8/17) **Includes lines of therapy given in the (neo)adjuvant setting if patient became metastatic within 12 months (N=4) 28
29 ER+/HER2 Breast Cancer Stage 3 locally advanced (unresectable), Stage 4 metastatic Endocrine & CDK 4/6i Therapy 1 st Line Chemo (30-33k Pts) Pivotal study 2 nd Line Chemo (26-28k Pts) 3rd Line Chemo (24-26k Pts) Evaluating Planned Ongoing 29
30 Sacituzumab Govitecan in Metastatic Non-Small Cell Lung Cancer
31 Low Response Rates for Chemotherapy in Previously-Treated mnsclc Treatment Phase N ORR PFS (months) OS (months) Source Docetaxel in 2 nd -line Non-squamous Docetaxel in 2 nd -line Squamous Docetaxel in 2 nd -line PD-L1 1% % % % Borghaei et al. N Engl J Med : Brahmer et al.; N Engl J Med : Herbst et al. Lancet (10027):
32 B e s t % c h a n g e in ta rg e t le s io n s fro m b a s e lin e Sacituzumab Govitecan in Pretreated mnsclc 54 patients enrolled Median number of prior lines: 3 (range, 2 7) ORR: 19% (9/47) Prior CPI: 14% (2/14) Median duration of response: 6.0 months (95% CI: 4.8, 8.3) Clinical benefit rate (CR+PR+SD 6 months): 32% Percent Reduction in Baseline Target Lesions P a rtia l r e s p o n s e (c o n fir m e d ) (P R ) U n c o n firm e d P R (P R u ) (s ta b le d is e a s e ) S ta b le d is e a s e P r o g r e s s io n + S q u a m o u s c e ll h is to lo g y 8 m g /k g s ta rtin g d o s e P r io r c h e c k p o in t in h ib ito r T x + e a rly C T a s s e s s m e n t a fte r 2 d o s e s Heist et al, Journal of Clinical Oncology 35(24): ,
33 Non-Small Cell Lung Cancer Stage 3 locally advanced (unresectable), Stage 4 metastatic 1 st Line Chemo + CPI Combo ( k Pts) Pivotal study 2 nd Line Chemo (75-85k Pts) 3rd Line Chemo (35-45k Pts) Evaluating Planned Ongoing 33
34 Additional Corporate Information
35 Broad Pipeline of ADC Therapies Research/Preclinical Phase 1 Phase 2 Phase 3 First-in-Class Antibody-Drug Conjugate (ADC) Programs Sacituzumab govitecan/immu-132 (anti-trop-2-sn-38 ADC) Metastatic triple-negative breast cancer (FDA granted BTD) Metastatic urothelial cancer Pivotal Metastatic ER+/HER2- breast cancer Solid tumors IITs FDA Review BLA Registration Labetuzumab govitecan/immu-130 (anti-ceacam5-sn-38 ADC) Metastatic colorectal cancer IMMU-140 (anti-hla-dr-sn-38 ADC) Solid and liquid cancers Other Product Candidates include Epratuzumab, Veltuzumab, Milatuzumab and IMMU-114 for Oncology and Autoimmune Disease Indications 35
36 Sufficient Cash Runway to Pursue Strategic Priorities Cash balance as of 6/30/2018 $639 Million Debt (convertible senior notes) $20 Million Basic shares outstanding (fully diluted) 187 (205) Million 36
Science-Based Innovation-Focused ADC Company. Corporate Overview June 2018
Science-Based Innovation-Focused ADC Company Corporate Overview June 2018 Forward-Looking Statements This presentation, in addition to historical information, contains certain forwardlooking statements
More informationIMMUNOMEDICS, INC. Advanced Antibody-Based Therapeutics
IMMUNOMEDICS, INC. Advanced Antibody-Based Therapeutics Oncology Autoimmune Diseases Rodman & Renshaw 19 th Annual Global Investment Conference Michael R. Garone, Principal Executive Officer and CFO Forward-Looking
More informationCorporate Overview. January 2018
Corporate Overview January 2018 Forward-Looking Statements This presentation, in addition to historical information, contains certain forwardlooking statements made pursuant to the Private Securities Litigation
More informationPatient-Centric Science-Based Performance-Driven Corporate Overview
Patient-Centric Science-Based Performance-Driven Corporate Overview May 2018 Forward-Looking Statements This presentation, in addition to historical information, contains certain forwardlooking statements
More informationIMMUNOMEDICS, INC. November Advanced Antibody-Based Therapeutics. Oncology Autoimmune Diseases
IMMUNOMEDICS, INC. Advanced Antibody-Based Therapeutics Oncology Autoimmune Diseases November 2017 Forward-Looking Statements This presentation, in addition to historical information, contains certain
More informationPatient-Centric Science-Based Performance-Driven
Patient-Centric Science-Based Performance-Driven Cowen & Co. 38 th Annual Health Care Conference Michael Pehl, President and Chief Executive Officer March 12, 2018 Forward-Looking Statements This presentation,
More informationSan Antonio Breast Cancer Symposium December 5-9, 2017
Sacituzumab Govitecan (IMMU-132), an Anti-Trop-2-SN-38 Antibody-Drug Conjugate, as 3rd-line Therapeutic Option for Patients With Relapsed/Refractory Metastatic Triple-Negative Breast Cancer (mtnbc): Efficacy
More informationIMMUNOMEDICS, INC. Advanced Antibody-Based Therapeutics. Jefferies 2014 Global Healthcare Conference Cynthia L. Sullivan, President and CEO
IMMUNOMEDICS, INC. Advanced Antibody-Based Therapeutics Oncology Autoimmune Diseases Jefferies 2014 Global Healthcare Conference Cynthia L. Sullivan, President and CEO Forward-Looking Statements This presentation,
More informationIMMUNOMEDICS, INC. Advanced Antibody-Based Therapeutics. Jefferies 2015 Global Healthcare Conference Peter P. Pfreundschuh, VP Finance and CFO
IMMUNOMEDICS, INC. Advanced Antibody-Based Therapeutics Oncology Autoimmune Diseases Jefferies 2015 Global Healthcare Conference Peter P. Pfreundschuh, VP Finance and CFO Forward-Looking Statements This
More information300 The American Road, Morris Plains, New Jersey (973) Fax (973)
IMMUNOMEDICS, INC. 300 The American Road, Morris Plains, New Jersey 07950 (973) 605-8200 Fax (973) 605-8282 PUBLISHED RESULTS FROM CLINICAL TRIALS DEMONSTRATE THERAPEUTIC POTENTIAL FOR IMMUNOMEDICS SACITUZUMAB
More informationInvestor Event at SABCS. December 2017
Investor Event at SABCS December 2017 Forward-Looking Statements This presentation, in addition to historical information, contains certain forwardlooking statements made pursuant to the Private Securities
More informationMETRIC Study Key Eligibility Criteria
The METRIC Study METRIC Study Key Eligibility Criteria The pivotal METRIC Study is evaluating glembatumumab vedotin in patients with gpnmb overexpressing metastatic triple-negative breast cancer (TNBC).
More informationInvestor Call. May 19, Nasdaq: IMGN
Investor Call May 19, 2017 Nasdaq: IMGN Forward-Looking Statements This presentation includes forward-looking statements based on management's current expectations. These statements include, but are not
More informationCorporate Overview. May 2017 NASDAQ: CYTR
Corporate Overview May 2017 NASDAQ: CYTR CytRx Safe Harbor Statement THIS PRESENTATION CONTAINS FORWARD-LOOKING STATEMENTS THAT INVOLVE CERTAIN RISKS AND UNCERTAINTIES. ACTUAL RESULTS COULD DIFFER MATERIALLY
More informationNovel Chemotherapy Agents for Metastatic Breast Cancer. Joanne L. Blum, MD, PhD Baylor-Sammons Cancer Center Dallas, TX
Novel Chemotherapy Agents for Metastatic Breast Cancer Joanne L. Blum, MD, PhD Baylor-Sammons Cancer Center Dallas, TX New Chemotherapy Agents in Breast Cancer New classes of drugs Epothilones Halichondrin
More informationEdith A. Perez, Ahmad Awada, Joyce O Shaughnessy, Hope Rugo, Chris Twelves, Seock-Ah Im, Carol Zhao, Ute Hoch, Alison L. Hannah, Javier Cortes
BEACON: A Phase 3 Open-label, Randomized, Multicenter Study of Etirinotecan Pegol (EP) versus Treatment of Physician s Choice (TPC) in Patients With Locally Recurrent or Metastatic Breast Cancer Previously
More informationGenta Incorporated. A Multiproduct Late-Stage Oncology Company
Genta Incorporated A Multiproduct Late-Stage Oncology Company This presentation may contain forward-looking statements with respect to business conducted by Genta Incorporated. By their nature, forward-looking
More informationNew chemotherapy drugs in metastatic breast cancer. Guy Jerusalem, MD, PhD
New chemotherapy drugs in metastatic breast cancer Guy Jerusalem, MD, PhD MBC Patients survival over time Median survival increases over time, but is still measured in months This is not yet a chronic
More informationThe next wave of successful drug therapy strategies in HER2-positive breast cancer. Hans Wildiers University Hospitals Leuven Belgium
The next wave of successful drug therapy strategies in HER2-positive breast cancer Hans Wildiers University Hospitals Leuven Belgium Trastuzumab in 1st Line significantly improved the prognosis of HER2-positive
More informationDetermined to realize a future in which people with cancer live longer and better than ever before
Determined to realize a future in which people with cancer live longer and better than ever before 3Q 2018 EARNINGS PRESENTATION NOVEMBER 2018 1 Forward-looking statements disclosure This presentation
More informationContemporary Chemotherapy-Based Strategies for First-Line Metastatic Breast Cancer
Contemporary Chemotherapy-Based Strategies for First-Line Metastatic Breast Cancer Hope S. Rugo, MD Professor of Medicine Director, Breast Oncology and Clinical Trials Education University of California
More informationRecent advances in the management of metastatic breast cancer in older adults
Recent advances in the management of metastatic breast cancer in older adults Laura Biganzoli Medical Oncology Dept New Hospital of Prato Istituto Toscano Tumori Italy Important recent advances in the
More informationCorporate Overview. July 2016 NASDAQ: CYTR
Corporate Overview July 2016 NASDAQ: CYTR CytRx Safe Harbor Statement THIS PRESENTATION CONTAINS FORWARD-LOOKING STATEMENTS THAT INVOLVE CERTAIN RISKS AND UNCERTAINTIES ASSOCIATED WITH A DEVELOPMENT-STAGE
More informationEvolving Paradigms in HER2+ MBC: Strategies for Individualizing Therapy with Available Agents
Evolving Paradigms in HER2+ MBC: Strategies for Individualizing Therapy with Available Agents Kimberly L. Blackwell MD Professor Department of Medicine and Radiation Oncology Duke University Medical Center
More informationThird Quarter 2015 Earnings Call. November 9, 2015
Third Quarter 2015 Earnings Call November 9, 2015 Forward-Looking Statements All of the statements in this presentation that are not statements of historical facts constitute forward-looking statements
More informationExpert Review: The Role of PARP Inhibition in the Treatment of Breast Cancer. Reference Slides
Expert Review: The Role of PARP Inhibition in the Treatment of Breast Cancer Reference Slides Overview BRCA Mutations and Breast Cancer Patients with BRCA mutations have an estimated 55% to 65% cumulative
More informationIpilimumab ASCO Data Review and Discussion Webcast. Monday, June 2, 2008
Ipilimumab ASCO Data Review and Discussion Webcast Monday, June 2, 2008 Slide 2 Forward Looking Statements Except for historical information, the matters contained in this slide presentation may constitute
More informationAACR 2018 Investor Meeting
AACR 218 Investor Meeting April 16, 218 1 Forward-Looking Information This presentation contains statements about the Company s future plans and prospects that constitute forward-looking statements for
More informationSTUDY FINDINGS PRESENTED ON TAXOTERE REGIMENS IN HEAD AND NECK, LUNG AND BREAST CANCER
Contact: Anne Bancillon + 33 (0)6 70 93 75 28 STUDY FINDINGS PRESENTED ON TAXOTERE REGIMENS IN HEAD AND NECK, LUNG AND BREAST CANCER Key results of 42 nd annual meeting of the American Society of Clinical
More informationKarcinom dojke. PANEL: Semir Bešlija, Zdenka Gojković, Robert Šeparović, Tajana Silovski
Karcinom dojke PANEL: Semir Bešlija, Zdenka Gojković, Robert Šeparović, Tajana Silovski MBC: HER2 PHEREXA: Study Design Multicenter, randomized, open-label phase III trial Stratified by prior CNS disease,
More informationImmunoconjugates in Both the Adjuvant and Metastatic Setting
Immunoconjugates in Both the Adjuvant and Metastatic Setting Mark Pegram, M.D. Director, Stanford Breast Oncology Program Co-Director, Molecular Therapeutics Program Trastuzumab Treatment of Breast Tumor
More informationCancer du sein métastatique et amélioration de la survie Pr. X. Pivot
Cancer du sein métastatique et amélioration de la survie Pr. X. Pivot Date of preparation: November 2015. EU0250i TTP/PFS Comparaisons First line metastatic breast cancer Monotherapy Docetaxel Chan 1999
More informationTARGET A BETTER NOW FORWARD-LOOKING STATEMENTS NASDAQ: IMGN. Current as of January 2018
NASDAQ: IMGN TARGET A BETTER NOW Current as of January 2018 FORWARD-LOOKING STATEMENTS This presentation includes forward looking statements based on management's current expectations. These statements
More informationRuth M. O Regan, MD Professor and Vice-Chair for Educational Affairs, Department of Hematology and Medical Oncology, Emory University, Chief of
Review of triple negative breast cancer and new agents GASCO Review of SABCS 2014 January 10 th 2015, Atlanta, GA Ruth M. O Regan, MD Professor and Vice-Chair for Educational Affairs, Department of Hematology
More informationR&D Conference Call. CHUGAI PHARMACEUTICAL CO., LTD. Department Manager of Oncology Lifecycle Management Dept. Megumi Uzu.
R&D Conference Call CHUGAI PHARMACEUTICAL CO., LTD. Department Manager of Oncology Lifecycle Management Dept. Megumi Uzu July 4, 2016 Forward-Looking Statements This presentation may include forward-looking
More informationG1 Corporate Overview March 11, 2019
G1 Corporate Overview March 11, 2019 www.g1therapeutics.com NASDAQ: GTHX 1 Forward-looking statements This presentation and the accompanying oral commentary contain forward-looking statements within the
More informationCorporate Overview. February 2018 NASDAQ: CYTR
Corporate Overview February 2018 NASDAQ: CYTR CytRx Safe Harbor Statement THIS PRESENTATION CONTAINS FORWARD-LOOKING STATEMENTS THAT INVOLVE CERTAIN RISKS AND UNCERTAINTIES. ACTUAL RESULTS COULD DIFFER
More informationImmune checkpoint blockade in lung cancer
Immune checkpoint blockade in lung cancer Raffaele Califano Department of Medical Oncology The Christie and University Hospital of South Manchester, Manchester, UK Outline Background Overview of the data
More informationTriple Negative Breast Cancer: Part 2 A Medical Update
Triple Negative Breast Cancer: Part 2 A Medical Update April 29, 2015 Tiffany A. Traina, MD Breast Medicine Service Memorial Sloan Kettering Cancer Center Weill Cornell Medical College Overview What is
More informationImmunotherapy for NSCLC: Current State of the Art and Future Directions. H. Jack West, MD Swedish Cancer Institute Seattle, Washington, United States
Immunotherapy for NSCLC: Current State of the Art and Future Directions H. Jack West, MD Swedish Cancer Institute Seattle, Washington, United States Which of the following statements regarding immunotherapy
More informationClinical Research on PARP Inhibitors and Triple-Negative Breast Cancer (TNBC)
Clinical Research on PARP Inhibitors and Triple-Negative Breast Cancer (TNBC) Eric P Winer, MD Disclosures for Eric P Winer, MD No real or apparent conflicts of interest to disclose Key Topics: PARP and
More informationClovis Oncology Announces Q Operating Results and Corporate Update. November 3, :05 PM ET
Clovis Oncology Announces Q3 2016 Operating Results and Corporate Update November 3, 2016 4:05 PM ET Rucaparib New Drug Application (NDA) accepted for Priority Review in the treatment of advanced BRCA-mutant
More informationImmune Checkpoint Inhibitors for Lung Cancer William N. William Jr.
Immune Checkpoint Inhibitors for Lung Cancer William N. William Jr. Diretor de Onco-Hematologia Hospital BP, A Beneficência Portuguesa Non-Small Cell Lung Cancer PD-1/PD-L1 Inhibitors in second-line therapy
More informationChemotherapy for Advanced Gastric Cancer
Chemotherapy for Advanced Gastric Cancer Andrés Cervantes Professor of Medicine DISCLOSURE OF INTEREST Employment: None Consultant or Advisory Role: Merck Serono, Roche, Beigene, Bayer, Servier, Lilly,
More informationCENTENE PHARMACY AND THERAPEUTICS DRUG REVIEW 3Q17 April May
BRAND NAME Keytruda GENERIC NAME Pembrolizumab MANUFACTURER Merck & Co., Inc. DATE OF APPROVAL Non-small cell lung cancer (NSCLC) indication: May 10, 2017 Urothelial carcinoma indication: May 18, 2017
More informationREWRITING CANCER TREATMENT THROUGH EPIGENETIC MEDICINES
REWRITING CANCER TREATMENT THROUGH EPIGENETIC MEDICINES May 18, 2017 Molecularly Defined Solid Tumor Program Update FORWARD-LOOKING STATEMENTS Any statements in this press release about future expectations,
More informationBreast Cancer: ASCO Poster Review
Breast Cancer: ASCO Poster Review Carmen Criscitiello, MD, PhD Istituto Europeo di Oncologia Milano HER2+ SUBTYPE Research questions in early HER2+ BC De-escalation of toxicity without compromising efficacy
More informationJuly, ArQule, Inc.
July, 2012 Safe Harbor This presentation and other statements by ArQule may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act with respect to clinical
More informationLION. Corporate Presentation June 2016 BIOTECHNOLOGIES. Leadership & Innovation in Oncology
LION BIOTECHNOLOGIES Leadership & Innovation in Oncology Corporate Presentation June 2016 Forward-Looking Statements This presentation contains forward-looking statements within the meaning of the Private
More informationImmunotherapy for Breast Cancer. Aurelio B. Castrellon Medical Oncology Memorial Healthcare System
Immunotherapy for Breast Cancer Aurelio B. Castrellon Medical Oncology Memorial Healthcare System Conflicts Research support : Cascadian therapeutics, Puma biotechnology, Odonate therapeutics, Pfizer,
More informationFOURTH QUARTER AND FULL YEAR 2018 FINANCIAL RESULTS AND BUSINESS UPDATE. Thursday, February 7, 2019
FOURTH QUARTER AND FULL YEAR 2018 FINANCIAL RESULTS AND BUSINESS UPDATE Thursday, February 7, 2019 Today s Speakers Overview and Key Highlights Clay Siegall, President & CEO Financial Results and Guidance
More informationFirst-Line Ribociclib + Letrozole for Postmenopausal Women With HR+, HER2-, Advanced Breast Cancer: First Results From the Phase III MONALEESA-2 Study
First-Line Ribociclib + Letrozole for Postmenopausal Women With HR+, HER2-, Advanced Breast Cancer: First Results From the Phase III MONALEESA-2 Study Abstract LBA1 Hortobagyi GN, Stemmer SM, Burris HA,
More informationARIAD Pharmaceuticals, Inc.
ARIAD Pharmaceuticals, Inc. June 8, 2016 David Sachs Non-small cell lung cancer 1 ARIAD clinical trial patient Some of the statements in this presentation constitute forward looking statements under the
More informationOvercoming resistance to endocrine or HER2-directed therapy
Overcoming resistance to endocrine or HER2-directed therapy Jane Lowe Meisel, MD Assistant Professor of Hematology and Medical Oncology Winship Cancer Institute at Emory University 1 Background While most
More informationMERCK ONCOLOGY OVERVIEW ASCO 2018 JUNE 4, 2018
MERCK ONCOLOGY OVERVIEW ASCO 218 JUNE 4, 218 Forward-Looking Statement of Merck & Co., Inc., Kenilworth, NJ, USA This presentation of Merck & Co., Inc., Kenilworth, N.J., USA (the company ) includes forward
More informationTarge:ng HER2 in Metasta:c Breast Cancer in 2014
Targe:ng HER2 in Metasta:c Breast Cancer in 2014 Kimberly L. Blackwell MD Professor Department of Medicine and Radia:on Oncology Duke University Medical Center Director, Breast Cancer Program Duke Cancer
More informationMetastatic NSCLC: Expanding Role of Immunotherapy. Evan W. Alley, MD, PhD Abramson Cancer Center at Penn Presbyterian
Metastatic NSCLC: Expanding Role of Immunotherapy Evan W. Alley, MD, PhD Abramson Cancer Center at Penn Presbyterian Disclosures: No relevant disclosures Please note that some of the studies reported in
More informationII sessione. Immunoterapia oltre la prima linea. Alessandro Tuzi ASST Sette Laghi, Varese
II sessione Immunoterapia oltre la prima linea Alessandro Tuzi ASST Sette Laghi, Varese AGENDA Immunotherapy post-chemo ( true 2/3L ) Immunotherapy in oncogene addicted NSCLC (yes/no? when?) Immunotherapy
More informationGASTRIC & PANCREATIC CANCER
GASTRIC & PANCREATIC CANCER ASCO HIGHLIGHTS 2005 Fadi Sami Farhat, MD Head of Hematology Oncology Division Hammoud Hospital University Medical Center Saida Lebanon Tel: +961 3 753 155 E-Mail: drfadi@drfadi.org
More informationFirst Phase 3 Results Presented for a PD-1 Immune Checkpoint Inhibitor
September 30, 2014 Positive Phase 3 Data for Opdivo (nivolumab) in Advanced Melanoma Patients Previously Treated with Yervoy @ (ipilimumab) Presented at the ESMO 2014 Congress First Phase 3 Results Presented
More informationPost-ASCO 2017 Cancer du sein Triple Négatif
Post-ASCO 217 Cancer du sein Triple Négatif A.Ladjeroud, K.Bouzid Centre Pierre et Marie Curie- Alger Oran, 3 Septembre 217 Phase III Investigation of Neoadjuvant Carboplatin ± Veliparib in Combination
More informationDetermined to realize a future in which people with cancer live longer and better than ever before CORPORATE PRESENTATION SEPTEMBER 2017
Determined to realize a future in which people with cancer live longer and better than ever before CORPORATE PRESENTATION SEPTEMBER 2017 1 Forward-looking statements disclosure This presentation contains
More informationBreast cancer update. Iryna Kuchuk, MD Oncology department Meir Medical Center
Breast cancer update Iryna Kuchuk, MD Oncology department Meir Medical Center Overview Cancer Death Rates* Among Women, US,1930-2009 Factors Associated with Reduction In Breast Cancer Mortality Early
More informationLa malattia triplo negativa metastatica: quali trattamenti nella pratica clinica?
2018 CARCINOMA MAMMARIO: I TRAGUARDI RAGGIUNTI E LE NUOVE SFIDE La malattia triplo negativa metastatica: quali trattamenti nella pratica clinica? Roma, 27 Ottobre 2018 Relatore: Francesca Poggio Disclosure
More informationChemotherapy and Immunotherapy in Combination Non-Small Cell Lung Cancer (NSCLC)
Chemotherapy and Immunotherapy in Combination Non-Small Cell Lung Cancer (NSCLC) Jeffrey Crawford, MD George Barth Geller Professor for Research in Cancer Co-Program Leader, Solid Tumor Therapeutics Program
More informationNew Drug Development in HER2+ Breast Cancer
New Drug Development in HER2+ Breast Cancer Philippe Aftimos, M.D. Senior Research Physician Clinical Pharmacology Unit Institut Jules Bordet Background Amplification of HER2 occurs in approximately 20%
More informationHer 2 Positive Advanced Breast Cancer: From Evidence to Practice
Her 2 Positive Advanced Breast Cancer: From Evidence to Practice Sunil Verma MD, FRCP(C) Medical Director, Tom Baker Cancer Center Professor and Head, Department of Oncology Cumming School of Medicine,
More informationMedia Release. Basel, 21 July 2017
Media Release Basel, 21 July 2017 CHMP recommends EU approval for Roche s TECENTRIQ (atezolizumab) in a specific type of metastatic lung and two types of metastatic bladder cancer TECENTRIQ as a potential
More informationLargos Supervivientes, Tenemos datos?
Largos Supervivientes, Tenemos datos? Javier Puente, MD, PhD Medical Oncology Department. Hospital Clinico San Carlos Associate Professor of Medicine. Complutense University of Madrid. Summary Snapshot
More informationDS-8201 Strategic Collaboration
DS-8201 Strategic Collaboration DAIICHI SANKYO CO., LTD George Nakayama Chairman and CEO March 29, 2019 Forward-Looking Statements Management strategies and plans, financial forecasts, future projections
More informationTargeted Agents as Maintenance Therapy. Karen Kelly, MD Professor of Medicine UC Davis Cancer Center
Targeted Agents as Maintenance Therapy Karen Kelly, MD Professor of Medicine UC Davis Cancer Center Disclosures Genentech Advisory Board Maintenance Therapy Defined Treatment Non-Progressing Patients Drug
More informationHighlights of. Metastatic & Advanced Breast Cancer
Highlights of Metastatic & Advanced Breast Cancer 1 Financial Disclosure(s) I currently have or have had the following relevant financial relations to disclose: Speaker s Bureau: Novartis 2 Off Label Use
More informationDetermined to realize a future in which people with cancer live longer and better than ever before CORPORATE PRESENTATION JUNE 2017
Determined to realize a future in which people with cancer live longer and better than ever before CORPORATE PRESENTATION JUNE 2017 1 Forward-looking statements disclosure This presentation contains forward-looking
More informationRevolutionizing the Treatment of Cancer
Revolutionizing the Treatment of Cancer June 2014 Safe Harbor Statement The statements that follow (including projections and business trends) are forward looking statements. Rexahn's actual results may
More informationDetermined to realize a future in which people with cancer live longer and better than ever before
Determined to realize a future in which people with cancer live longer and better than ever before 4Q 2016 EARNINGS PRESENTATION MARCH 2017 1 Forward-looking statements disclosure This presentation contains
More informationCheckpoint Inibitors for Bladder Cancer
Checkpoint Inibitors for Bladder Cancer Daniel P. Petrylak, MD Professor of Medicine and Urology Director, GU Translational Working Group Co Director, Signal Transduction Program Smilow Cancer Center,
More informationSponsor / Company: Sanofi Drug substance(s): SAR (iniparib)
These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert in the country of prescription. Sponsor / Company: Sanofi Drug substance(s):
More information33 rd Annual J.P. Morgan Healthcare Conference. January 2015
33 rd Annual J.P. Morgan Healthcare Conference January 2015 Forward-looking Statements This presentation contains forward-looking statements, which express the current beliefs and expectations of management.
More informationLonnie Moulder, CEO Leerink Global Healthcare Conference February 12, 2015
Lonnie Moulder, CEO Leerink Global Healthcare Conference February 12, 2015 Safe Harbor Statement Statements made in this presentation about TESARO, Inc. that are not descriptions of historical facts are
More informationNY-ESO SPEAR T-cells in Synovial Sarcoma
NY-ESO SPEAR T-cells in Synovial Sarcoma ASCO Update June 6, 2017 Disclaimer This presentation contains forward-looking statements, as that term is defined under the Private Securities Litigation Reform
More informationEribulin for locally advanced or metastatic breast cancer third line; monotherapy
Eribulin for locally advanced or metastatic breast cancer third line; monotherapy April 2009 This technology summary is based on information available at the time of research and a limited literature search.
More informationAVEO and Astellas Announce TAURUS Patient Preference Clinical Study Comparing Tivozanib with Sunitinib in First-Line Kidney Cancer
FOR IMMEDIATE RELEASE AVEO and Astellas Announce TAURUS Patient Preference Clinical Study Comparing Tivozanib with Sunitinib in First-Line Kidney Cancer Study designed to build upon safety profile demonstrated
More informationESMO 2016 * Investor Meeting October 9, *European Society of Medical Oncology, October 7-11, 2016 ESMO 2016 NOT FOR PRODUCT PROMOTIONAL USE
ESMO 2016 * Investor Meeting October 9, 2016 *European Society of Medical Oncology, October 7-11, 2016 1 Forward-Looking Information During this meeting, we will make statements about the Company s future
More informationAdvances in Breast Cancer Therapeutics in the Adjuvant and Metastatic Settings. Eve Rodler, MD University of California at Davis October 2016
Advances in Breast Cancer Therapeutics in the Adjuvant and Metastatic Settings Eve Rodler, MD University of California at Davis October 2016 17th Annual Advances in Oncology September 30-October 1, 2016
More informationA Fully Integrated Cancer Company.
A Fully Integrated Cancer Company. Jefferies 2015 Healthcare Conference June 2, 2015 Robert Mulroy, President & CEO Forward Looking Statements To the extent that statements contained in this presentation
More informationMerck ASCO 2015 Investor Briefing
Merck ASCO 2015 Investor Briefing Forward-Looking Statement This presentation includes forward-looking statements within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation
More informationLeading the Next Wave of Biotech Breakthroughs
Leading the Next Wave of Biotech Breakthroughs Corporate Extensive corporate assets Platforms Pipeline Partnerships Building a sustainable global business Platform licenses represent a source of non-dilutive
More informationNSCLC: immunotherapy as a first-line treatment. Paolo Bironzo Oncologia Polmonare AOU S. Luigi Gonzaga Orbassano (To)
NSCLC: immunotherapy as a first-line treatment Paolo Bironzo Oncologia Polmonare AOU S. Luigi Gonzaga Orbassano (To) The 800-pound gorilla Platinum-based chemotherapy is the SOC for 1st-line therapy in
More informationFORWARD II PROGRAM UPDATE
FORWARD II PROGRAM UPDATE NASDAQ: IMGN May 17, 2018 FORWARD-LOOKING STATEMENTS This presentation includes forward-looking statements based on management's current expectations. These statements include,
More informationNASDAQ: CYTR FIGHTING CANCER WITH CUTTING EDGE SCIENCE. Corporate Overview. July 2018
NASDAQ: CYTR Corporate Overview July 2018 CytRx Safe Harbor Statement THIS PRESENTATION CONTAINS FORWARD-LOOKING STATEMENTS THAT INVOLVE CERTAIN RISKS AND UNCERTAINTIES. ACTUAL RESULTS COULD DIFFER MATERIALLY
More informationManagement Guidelines and Targeted Therapies in Metastatic Non-Small Cell Lung Cancer: An Oncologist s Perspective
Management Guidelines and Targeted Therapies in Metastatic Non-Small Cell Lung Cancer: An Oncologist s Perspective Julie R. Brahmer, M.D. Associate Professor of Oncology The Sidney Kimmel Comprehensive
More informationCorporate Presentation
Corporate Presentation Leerink Global Healthcare Conference February 14 th -15 th, 2018 C O N F I D E N T I A L a n d P R O P R I E T A R Y Forward Looking Statements / Safe Harbor This presentation contains
More informationDetermined to realize a future in which people with cancer live longer and better than ever before 4Q18 EARNINGS PRESENTATION MARCH 2019
Determined to realize a future in which people with cancer live longer and better than ever before 4Q18 EARNINGS PRESENTATION MARCH 2019 Forward-looking statements disclosure This presentation contains
More informationLead team presentation Eribulin for treating locally advanced or metastatic breast cancer after two or more prior chemotherapy regimens STA
For projector and public [noacic] Lead team presentation Eribulin for treating locally advanced or metastatic breast cancer after two or more prior chemotherapy regimens STA 1 st Appraisal Committee meeting
More informationRevolutionizing the Treatment of Cancer
Revolutionizing the Treatment of Cancer January 2014 Safe Harbor Statement The statements that follow (including projections and business trends) are forward looking statements. Rexahn's actual results
More informationRevolutionizing the Treatment of Cancer
Revolutionizing the Treatment of Cancer March 2014 Safe Harbor Statement The statements that follow (including projections and business trends) are forward-looking statements. Rexahn's actual results may
More informationMetronomic chemotherapy for breast cancer
Metronomic chemotherapy for breast cancer M. Colleoni International Breast Cancer Study Group (IBCSG), Division of Medical Senology, European Institute of Oncology Metronomic Scheduling and Inhibition
More information